In this issue:
Reducing the risk of developing PsA
bDMARDs and risk of PsA in chronic plaque psoriasis
Management of psoriasis patients during the COVID-19 pandemic
Biologics and small molecules for elderly patients with psoriasis
Prediction and verification of the effect of psoriasis on CHD
Safety of ixekizumab in adult patients with moderate-to-severe psoriasis
Very-low-calorie ketogenic diet in psoriasis and obesity
Metabolic comorbidities and cardiovascular disease in paediatric psoriasis
Risk of IBD in patients initiating IL-17 inhibitors
Biologic therapy and development of PsA
Please login below to download this issue (PDF)